BEAM vs IDYA
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
BEAM · Beam Therapeutics$26.41 ▲ 2.09%
IDYA · IDEAYA Biosciences$31.24 ▲ 1.93%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- BEAM +22.0%
- IDYA +1.1%
Head to head
| Metric | BEAM | IDYA |
|---|---|---|
| Price | $26.41 | $31.24 |
| Change today | ▲ 2.09% | ▲ 1.93% |
| Market cap | $2.73B | $3.02B |
| Return, 3 months | -3.2% | -15.0% |
| Return, year to date | -4.7% | -9.6% |
| Return, 1 year | +18.9% | +3.3% |
| P/E (TTM) | -30.0 | -6.9 |
| P/B | 2.9 | 2.8 |
| P/E percentile vs own 5y | 7th | 43rd |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -94.2% | – |
| Net profit growth (YoY) | -20.1% | -45.1% |
| Gross margin | – | – |
| Operating margin | -242.3% | -92.7% |
| Net margin | -55.4% | -74.8% |
| Return on equity | -8.2% | -16.2% |
| Analyst target vs. price | +110.8% | +62.0% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 52 | 37 |
| 30-day volatility | 67.3% | 43.5% |
| Max drawdown, 1 year | -39.1% | -27.8% |
| Trend read | Leaning bullish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- IDYA is the largest of the group by market value.
- BEAM has returned the most over the past year.
- BEAM carries the lowest trailing P/E.
- BEAM keeps the most profit per dollar of sales.
- IDYA has been the calmest stock over the last 30 days.